IP Library Granted Patent US 8,772,241
Granted Patent B2
US 8,772,241 · App. 13/701,465 · Granted Jul 8, 2014

Peptide and use thereof

Inventors: Hae Jin Kim (Daejeon, KR); Je Wook Lee (Daejeon, KR); Young Joon Kwon (Daejeon, KR); Eun Joung Moon (Daejeon, KR)
Assignee: Ensoltek Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,241
App. No.
13/701,465
Granted
Jul 8, 2014
Kind
B2
Abstract

The present invention provides a peptide represented by formula (I) of X 1 -Leu-X 2 -Leu-X 3 wherein X 1 represents Glu or Asp, X 2 represents His, Lys or Arg, X 3 represents Asp or Glu, with Glu, Asp, Leu, His, Lys and Arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and TGFβ1. The above-mentioned peptide or a pharmaceutically acceptable salt thereof is effective for the treatment and/or prevention of cartilage damage and/or arthritis and is capable of exhibiting effects of the regeneration of cartilage tissue, the inhibition of the expression of cartilage tissue matrix degrading enzyme and/or the inhibition of cartilage tissue ossification.

Claims (12)

1. An isolated peptide consisting of the amino acid sequence of formula (I)

X1-Leu-X2-Leu-X3  (I)

or pharmaceutically acceptable salt thereof,

wherein X1 is Glu or Asp; X2 is His, Lys or Arg; X3 is Asp or Glu, and Glu, Asp, Leu, His, Lys, and Arg are glutamic acid, aspartic acid, leucine, histidine, lysine, and arginine, respectively.

2. An isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1 (Glu-Leu-His-Leu-Asp) or pharmaceutically acceptable salt thereof,

wherein and Glu, Asp, Leu, His, Lys, and Arg are glutamic acid, aspartic acid, leucine, histidine, lysine, and arginine, respectively.

3. A composition comprising the peptide of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

4. The composition according to claim 3 , wherein the composition is a pharmaceutical composition.

5. A composition comprising the peptide of claim 1 or a pharmaceutically acceptable salt thereof and transforming growth factor beta 1 (TGFβ1).

6. A composition comprising the peptide of claim 2 or a pharmaceutically acceptable salt thereof as an active ingredient.

7. A composition comprising the peptide of claim 2 or a pharmaceutically acceptable salt thereof and transforming growth factor beta 1 (TGFβ1).

8. The composition of claim 3 , wherein administering the composition promotes the production of type II collagen.

Assignments (2)
CHANGE OF NAME Recorded Mar 6, 2020
From: ENSOLTEK CO., LTD.
To: ENSOL BIOSCIENCES INC.
Reel/Frame 052117/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2012
From: KIM, HAE JIN; LEE, JE WOOK; KWON, YOUNG JOON; MOON, EUN JOUNG
To: ENSOLTEK CO., LTD.
Reel/Frame 029389/0335 →
Priority Claims (1)
KR 10-2010-0062467 · Jun 30, 2010 · national
Continuity (1)
Related Publication 20130109626A1 · May 2, 2013